In response to this positive data, NOPR formally asked CMS to reconsider the current National Coverage decision on oncologic use of FDG-PET and to end the data collection requirements for diagnosis, staging and restaging. CMS issued a Call for Comments for interested parties, including physicians, advocacy groups and imaging societies, to contribute additional information prior to a final reimbursement decision. The comment period ended Oct. 17, and a decision is expected early next year.

NOPR is sponsored by the Academy of Molecular Imaging (AMI), and managed by the American College of Radiology (ACR) and ACR Imaging Network (ACRIN). The registry received input from-and is endorsed by-ACR, the American Society for Clinical Oncology (ASCO) and SNM. The NOPR Working Group was chaired by Bruce Hillner, M.D., of Virginia Commonwealth University and co-chaired by Barry Siegel, M.D., Washington University; R. Edward Coleman, M.D., Duke University; and Anthony Shields, M.D., Wayne State University.


About SNM
SNM is an international scientific and medical organization dedicated to raising public awareness about what molecular imaging is and how it can help provide patients with the best health care possible. SNM members specialize in molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated.

SNM's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snm.org.

Read DOTmed News coverage of recent significant NOPR findings:
https://www.dotmed.com/news/story/6882/
https://www.dotmed.com/news/story/5873/

Back to HCB News

More Industry Headlines